• 🌎 Worldwide
    • πŸ‡ΊπŸ‡Έ U.S.
    • πŸ‡¨πŸ‡¦ Canada
    • πŸ‡¬πŸ‡§ United Kingdom
    • 🌏 Asia
    • 🌍 Europe
    • 🌎 Latin America
    • 🌏 Oceania and Australasia
The Daily Marijuana Observer
SUBSCRIBE
  • Home
  • Latest
  • πŸ”’ PRO
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
  • Home
  • Latest
  • πŸ”’ PRO
  • Business
  • Investments
  • Law
  • People
  • Health
  • Databases
No Result
View All Result
The Daily Marijuana Observer
No Result
View All Result
Home Investments Marijuana Stocks

Lexaria Bioscience Continues to Grow its Patent Portfolio

TheNewswire by TheNewswire
September 22, 2020
in Marijuana Stocks, Press Releases
Cannabis Cultivation News
62
SHARES
ShareShare

Kelowna, British Columbia – TheNewswire – September 22, 2020 – Lexaria Bioscience Corp. (OTC:LXRP) (CSE:LXX) (CNSX:LXX.CN) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announces that it has received another new granted patent in the USA.

Lexaria has been granted U.S. Patent No. 10,756,180 pursuant to the Notice of Allowance it received from the United States Patent and Trademark Office (“USPTO”) for patent application number 16/497,920 previously announced on April 23, 2020.

This new patent provides patent claims that protect the use of Lexaria’s DehydraTECH(TM) technology together with cannabinoids, nicotine, nonsteroidal anti-inflammatory drugs, or vitamins in mix and serve beverage formats. The patent is entitled “Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof”. This signifies another addition to Lexaria’s first patent family, under which nine US patents have now been granted.

Lexaria has also responded to patent office queries in Europe, India, Mexico, Australia, USA, Japan and Canada in recent weeks and although the Company does not expect all its applications to be successful, it is optimistic of additional patent grants in some of these locations soon.

Lexaria currently has 17 granted patents, with 9 granted in the US and 8 in Australia, along with roughly 60 patent applications pending throughout the world. The granted patents cover delivery of cannabinoids, NSAIDs, nicotine and fat-soluble vitamins. Patents are pending for the delivery of antiviral drugs, human hormones such as testosterone and estrogen, phosphodiesterase inhibitors and more.

About Lexaria

Lexaria Bioscience Corp.’s (OTCQX: LXRP, CSE: LXX) proprietary drug delivery technology, DehydraTECH(TM), improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 – 2 hours to 10 – 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, please visit http://www.lexariabioscience.com.

FORWARD-LOOKING STATEMENTS

This release includes forward-looking statements. Statements as such term is defined under applicable securities laws. These statements may be identified by words such as “anticipate,” “if,” “believe,” “plan,” “estimate,” “expect,” “intend,” “may,” “could,” “should,” “will,” and other similar expressions. Such forward-looking statements in this press release include, but are not limited to, all statements by the company related to patents granted or pending. Such forward-looking statements are estimates reflecting the Company’s best judgment based upon current information and involve a number of risks and uncertainties, and there can be no assurance that the Company will actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements. As such, you should not place undue reliance on these forward-looking statements. Factors which could cause actual results to differ materially from those estimated by the Company include, but are not limited to, government regulation and regulatory approvals, managing and maintaining growth, the effect of adverse publicity, litigation, competition, scientific discovery, the patent application and approval process, potential adverse effects arising from the testing or use of products utilizing the DehydraTECH technology, the Company’s ability to maintain existing collaborations and realize the benefits thereof, and other factors which may be identified from time to time in the Company’s public announcements and periodic filings with the US Securities and Exchange Commission on EDGAR. There is no assurance that existing capital is sufficient for the Company’s needs or that it will be able to raise additional capital. There is no assurance the Company will be capable of developing, marketing, licensing, or selling edible products containing any active ingredient. There is no assurance that any planned corporate activity, scientific research or study, business venture, letter of intent, technology licensing pursuit, patent application or allowance, consumer study, or any initiative will be pursued, or if pursued, will be successful. There is no assurance that any of Lexaria’s postulated uses, benefits, or advantages for the patented and patent-pending technology will in fact be realized in any manner or in any part. No statement herein has been evaluated by the Food and Drug Administration (FDA). Lexaria-associated products are not intended to diagnose, treat, cure or prevent any disease.

Any forward-looking statements contained in this release speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise, except as otherwise required by law.

The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

INVESTOR CONTACT:

ir@lexariabioscience.com

Phone: 866-221-3341

Copyright (c) 2020 TheNewswire – All rights reserved.

Share this:

  • Click to email this to a friend (Opens in new window)
  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on LinkedIn (Opens in new window)
  • Click to share on Reddit (Opens in new window)
  • Click to share on Telegram (Opens in new window)
  • Click to share on WhatsApp (Opens in new window)
  • Click to share on Pinterest (Opens in new window)
  • Click to share on Tumblr (Opens in new window)
  • Click to share on Pocket (Opens in new window)
Tags: CSE:LXXLexaria Bioscience Corp.OTC:LXRP

Get Real-Time Updates from MJobserver.com

Unsubscribe
TheNewswire

TheNewswire

A fully-accredited compliance service since 2004, TheNewswire provides distribution and filing agency services to hundreds of clients – domestically and internationally.

Related Posts

AgraFlora Subsidiary Farmako Submits Application for EU-GMP Certification and Manufacturing/Import License
Intellectual Property

Lexaria Bioscience Granted First European Patent for DehydraTECH(TM) Technology

October 21, 2020
Health Canada Licensed Cannabis Producer and Processor Stocks
Press Releases

Lexaria Bioscience Applies for NIH Grant for COVID-19 Therapy Studies and Receives New Expanded Health Canada License

June 18, 2020
TILT Holdings Announces Forfeiture of 60 Million Stock Options from Founders
Marijuana Stocks

Lexaria Awards Options

December 30, 2019
Marijuana Stocks - Gainers
Marijuana Stocks

5 of Today’s Biggest Marijuana Stock Gainers – Monday, October 14, 2019

October 14, 2019
Marijuana Stocks - Gainers
Marijuana Stocks

5 of Today’s Biggest Marijuana Stock Gainers – Tuesday, October 8, 2019

October 8, 2019
Marijuana Stocks - Gainers
Trading

5 of Today’s Biggest Marijuana Stock Gainers – Friday, August 9, 2019

August 9, 2019
Load More
Next Post
Amended: Naturally Splendid Closes Private Placement and Secures Laboratory Facility

Amended: Naturally Splendid Closes Private Placement and Secures Laboratory Facility

πŸ”Ž Search Marijuana Stocks

πŸ“° Recent News

  • American Green’s Grand Opening on Amazon is a Success
  • The Jordre Well, LLC Submits CBD-Infused Coffee Samples to Labs for Testing
  • Unifor and Aleafia Health Enter Exclusive Agreement to Support Medical Cannabis Coverage for Members
  • BevCanna’s Pure Therapy Reports Record Monthly Revenue
  • CBD Vaping: Why So Many People Have Started
Facebook Twitter Instagram LinkedIn Youtube

DMO PRO Subscription

  • πŸ“Š Free vs. Pro
  • πŸ“« Register
  • πŸ‘€ My Account
  • πŸ’³ Payment History
  • πŸ”‘ Recover Password
  • πŸ”“ Login
  • πŸ”’ Logout

Cannabis News by Region

  • πŸ‡ΊπŸ‡Έ United States
  • πŸ‡¨πŸ‡¦ Canada
  • πŸ‡¬πŸ‡§ United Kingdom
  • 🌏 Asia
  • 🌍 Europe
  • 🌎 Latin America
  • 🌏 Oceania and Australasia

Cannabis Tools & Resources

  • πŸ“… Calendar
  • πŸ“Š Databases
  • πŸ“‡ Directories
  • πŸ“™ Glossary
  • πŸ”” RSS Feeds
  • πŸ“Ί Videos

Find Cannabis Business Services

  • βš–οΈ Attorneys & Law Firms
  • πŸ“Š Accountants & Accounting Firms
  • πŸ’‘ Consultants & Consulting Firms
  • πŸ“² Marketing Agencies & Firms

The Daily Marijuana Observer

  • Subscribe
  • About MJobserver.com
  • Affiliate Marketing Disclosure
  • Legal Disclaimer
  • Privacy Policy
  • Contact Us

Advertise with Us

  • πŸ‘€ Advertise
  • πŸ“£ DMO Newswire
  • πŸ“‡ List in Our Databases

Β© 2018 - 2020 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerβ„’ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

No Result
View All Result
  • Home
  • Latest
  • πŸ”’ PRO
    • πŸ”’ A.M. Watchlist
    • πŸ”’ Analyst Action
  • πŸ’Ό Business
  • πŸ“ˆ Investments
    • πŸ“ˆ Stocks
    • πŸ’° ETFs and Funds
    • πŸ’­ Market Commentary
    • πŸ“° Press Releases
    • πŸ“… Earnings Calendar
  • βš–οΈ Law
    • Laws
    • Politics
    • Intellectual Property
    • Attorneys & Law Firms Database
  • πŸ‘₯ People
    • ⚽ Athletes
    • πŸ’Ό Executives
    • 🌟 Celebrities
    • πŸ›’ Consumers
    • βš•οΈ Doctors
    • πŸ’Š Patients
  • πŸ’Š Health
  • πŸ“‡ Databases
    • πŸ“ˆ Stock Databases
    • πŸ’° Fund Databases
    • πŸ’Ό Service Providers Databases
    • 🏦 Marijuana Stock Brokers
    • πŸ’² Marijuana Cryptocurrencies

Β© 2018 - 2020 D.M.O. Holdings Corp.
DISCLAIMER: DMO Holdings Corp., which owns The Daily Marijuana Observerβ„’ (MJobserver.com), is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. DMO Holdings Corp., which owns MJobserver.com, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. Before making specific investment decisions, readers should seek their own professional advice and that of their own professional financial adviser. DMO Holdings Corp. or its affiliates, which owns MJobserver.com, may be compensated for its services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two.

Login to your account below

Forgotten Password? Sign Up

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.